Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection

Y. Zhao, N. M. Katz, E. A. Lefrak, M. L. Foegh

Research output: Contribution to journalArticle

Abstract

Noninvasive methods for regular monitoring of cardiac transplant patients for acute rejection are preferable to the only currently accepted method involving frequent endomyocardial biopsies. Thromboxane A2 (TXA2) is synthesized in large amounts by monocytes/macrophages during organ graft rejection. It enhances T-lymphocyte clonal expansion and cytotoxic function as well as upregulating the major histocompatibility class II expression on antigen presenting cells. Experimentally increased urinary excretion of TXA2 metabolites is associated with cardiac transplant rejection. We therefore compared urinary immunoreactive thromboxane B2 (i-TXB2) levels to the rejection score of the endomyocardial biopsies. In addition we graded the degree of activated lymphocytes in peripheral blood. Urinary i-TXB2 was significantly higher in patients exhibiting medium to severe rejection than in patients without rejection (1236 ± 372 vs. 526 ± 57 pg/mL). The urine i- TXB2 (704 ± 48 pg/mL) of all patients who participated in this study, whose endomyocardial biopsy indicated rejection, was also significantly higher than in the non-rejecting group. Increased levels of urine i-TXB2 were associated with increased biopsy scores. Circulating activated lymphocytes was also significantly increased in patients with moderate/severe rejection compared to patients with no rejection (66 ± 11 vs. 39 ± 4 per mm (3)) (p <0.01). Further this study shows that urine i-TXB2 is associated with increased endomyocardial biopsy scores (acute rejection scores) and blood lymphocyte activation. Thus we conclude that urine i-TXB2 may be of potential value as a diagnostic screening test for helping identify cardiac transplant patients undergoing acute rejection.

Original languageEnglish (US)
Pages (from-to)881-889
Number of pages9
JournalProstaglandins
Volume54
Issue number6
DOIs
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Thromboxane B2
Transplants
Biopsy
Screening
Lymphocytes
Thromboxane A2
Urine
Blood
Graft Rejection
T-cells
Macrophages
Metabolites
Grafts
Histocompatibility
Antigen-Presenting Cells
Chemical activation
Lymphocyte Activation
Routine Diagnostic Tests
Monocytes
Monitoring

Keywords

  • Allograft
  • Cardiac transplantation
  • Diagnostic screening method
  • Rejection
  • Thromboxane
  • Urine thromboxane

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection. / Zhao, Y.; Katz, N. M.; Lefrak, E. A.; Foegh, M. L.

In: Prostaglandins, Vol. 54, No. 6, 12.1997, p. 881-889.

Research output: Contribution to journalArticle

Zhao, Y. ; Katz, N. M. ; Lefrak, E. A. ; Foegh, M. L. / Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection. In: Prostaglandins. 1997 ; Vol. 54, No. 6. pp. 881-889.
@article{977ba10e21484156a9a563b701526af0,
title = "Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection",
abstract = "Noninvasive methods for regular monitoring of cardiac transplant patients for acute rejection are preferable to the only currently accepted method involving frequent endomyocardial biopsies. Thromboxane A2 (TXA2) is synthesized in large amounts by monocytes/macrophages during organ graft rejection. It enhances T-lymphocyte clonal expansion and cytotoxic function as well as upregulating the major histocompatibility class II expression on antigen presenting cells. Experimentally increased urinary excretion of TXA2 metabolites is associated with cardiac transplant rejection. We therefore compared urinary immunoreactive thromboxane B2 (i-TXB2) levels to the rejection score of the endomyocardial biopsies. In addition we graded the degree of activated lymphocytes in peripheral blood. Urinary i-TXB2 was significantly higher in patients exhibiting medium to severe rejection than in patients without rejection (1236 ± 372 vs. 526 ± 57 pg/mL). The urine i- TXB2 (704 ± 48 pg/mL) of all patients who participated in this study, whose endomyocardial biopsy indicated rejection, was also significantly higher than in the non-rejecting group. Increased levels of urine i-TXB2 were associated with increased biopsy scores. Circulating activated lymphocytes was also significantly increased in patients with moderate/severe rejection compared to patients with no rejection (66 ± 11 vs. 39 ± 4 per mm (3)) (p <0.01). Further this study shows that urine i-TXB2 is associated with increased endomyocardial biopsy scores (acute rejection scores) and blood lymphocyte activation. Thus we conclude that urine i-TXB2 may be of potential value as a diagnostic screening test for helping identify cardiac transplant patients undergoing acute rejection.",
keywords = "Allograft, Cardiac transplantation, Diagnostic screening method, Rejection, Thromboxane, Urine thromboxane",
author = "Y. Zhao and Katz, {N. M.} and Lefrak, {E. A.} and Foegh, {M. L.}",
year = "1997",
month = "12",
doi = "10.1016/S0090-6980(97)00186-X",
language = "English (US)",
volume = "54",
pages = "881--889",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection

AU - Zhao, Y.

AU - Katz, N. M.

AU - Lefrak, E. A.

AU - Foegh, M. L.

PY - 1997/12

Y1 - 1997/12

N2 - Noninvasive methods for regular monitoring of cardiac transplant patients for acute rejection are preferable to the only currently accepted method involving frequent endomyocardial biopsies. Thromboxane A2 (TXA2) is synthesized in large amounts by monocytes/macrophages during organ graft rejection. It enhances T-lymphocyte clonal expansion and cytotoxic function as well as upregulating the major histocompatibility class II expression on antigen presenting cells. Experimentally increased urinary excretion of TXA2 metabolites is associated with cardiac transplant rejection. We therefore compared urinary immunoreactive thromboxane B2 (i-TXB2) levels to the rejection score of the endomyocardial biopsies. In addition we graded the degree of activated lymphocytes in peripheral blood. Urinary i-TXB2 was significantly higher in patients exhibiting medium to severe rejection than in patients without rejection (1236 ± 372 vs. 526 ± 57 pg/mL). The urine i- TXB2 (704 ± 48 pg/mL) of all patients who participated in this study, whose endomyocardial biopsy indicated rejection, was also significantly higher than in the non-rejecting group. Increased levels of urine i-TXB2 were associated with increased biopsy scores. Circulating activated lymphocytes was also significantly increased in patients with moderate/severe rejection compared to patients with no rejection (66 ± 11 vs. 39 ± 4 per mm (3)) (p <0.01). Further this study shows that urine i-TXB2 is associated with increased endomyocardial biopsy scores (acute rejection scores) and blood lymphocyte activation. Thus we conclude that urine i-TXB2 may be of potential value as a diagnostic screening test for helping identify cardiac transplant patients undergoing acute rejection.

AB - Noninvasive methods for regular monitoring of cardiac transplant patients for acute rejection are preferable to the only currently accepted method involving frequent endomyocardial biopsies. Thromboxane A2 (TXA2) is synthesized in large amounts by monocytes/macrophages during organ graft rejection. It enhances T-lymphocyte clonal expansion and cytotoxic function as well as upregulating the major histocompatibility class II expression on antigen presenting cells. Experimentally increased urinary excretion of TXA2 metabolites is associated with cardiac transplant rejection. We therefore compared urinary immunoreactive thromboxane B2 (i-TXB2) levels to the rejection score of the endomyocardial biopsies. In addition we graded the degree of activated lymphocytes in peripheral blood. Urinary i-TXB2 was significantly higher in patients exhibiting medium to severe rejection than in patients without rejection (1236 ± 372 vs. 526 ± 57 pg/mL). The urine i- TXB2 (704 ± 48 pg/mL) of all patients who participated in this study, whose endomyocardial biopsy indicated rejection, was also significantly higher than in the non-rejecting group. Increased levels of urine i-TXB2 were associated with increased biopsy scores. Circulating activated lymphocytes was also significantly increased in patients with moderate/severe rejection compared to patients with no rejection (66 ± 11 vs. 39 ± 4 per mm (3)) (p <0.01). Further this study shows that urine i-TXB2 is associated with increased endomyocardial biopsy scores (acute rejection scores) and blood lymphocyte activation. Thus we conclude that urine i-TXB2 may be of potential value as a diagnostic screening test for helping identify cardiac transplant patients undergoing acute rejection.

KW - Allograft

KW - Cardiac transplantation

KW - Diagnostic screening method

KW - Rejection

KW - Thromboxane

KW - Urine thromboxane

UR - http://www.scopus.com/inward/record.url?scp=0031283401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031283401&partnerID=8YFLogxK

U2 - 10.1016/S0090-6980(97)00186-X

DO - 10.1016/S0090-6980(97)00186-X

M3 - Article

C2 - 9533183

AN - SCOPUS:0031283401

VL - 54

SP - 881

EP - 889

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

IS - 6

ER -